stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Net income
Viridian Therapeutics, Inc.'s net income for fiscal 2025 was −$342.6M, compared with −$269.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$453.6M. Over the past ten years it has ranged from −$342.6M (fiscal 2025) to −$11.3M (fiscal 2015) — the current reading is the lowest in ten years. Net income has fallen for 4 consecutive fiscal years. Viridian Therapeutics, Inc. ranks 582nd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$342.6M | — |
| FY2024 | −$269.9M | — |
| FY2023 | −$237.7M | — |
| FY2022 | −$129.9M | — |
| FY2021 | −$79.4M | — |
| FY2020 | −$110.7M | — |
| FY2019 | −$41.9M | — |
| FY2018 | −$32.7M | — |
| FY2017 | −$26.5M | — |
| FY2016 | −$17.3M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$101.2M | — |
| Jun 2026 | −$127.1M | — |
| Mar 2026 | −$104.9M | — |
| Dec 2025 | −$120.4M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | $31.7M |
| ELVN Enliven Therapeutics, Inc. compare | −$105.9M |
| CELC Celcuity, Inc. compare | −$226.5M |
| DNLI Denali Therapeutics Inc. compare | −$314.4M |
| IDYA IDEAYA Biosciences, Inc. compare | −$420.0M |
| VRDN Viridian Therapeutics, Inc. | −$453.6M |
| DYN Dyne Therapeutics, Inc. compare | −$519.4M |
| VKTX Viking Therapeutics, Inc. compare | −$627.2M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$702.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on VRDN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement